ERC Starting Grant · 2022
Microbial Synthetic in vivo Cell Therapy Systems
Bacteria are among the most brilliant chemists on Earth. They are capable of producing a wealth of structurally diverse natural products with a wide range of applications in medicine, such as the treatment of infections and cancer. The synthetic production of microbial natural products and their transformation into pharmaceutical drugs is often a challenging, costly and time-consuming process due to the structural complexity of these molecules and the difficulties associated with drug solubility and formulation. An emerging new strategy in disease treatment aims to exploit beneficial intestinal microbes for ‘local’ drug production and delivery. Such commensal bacteria are safe, can be…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.